Announcements Trials
Browse Landscape

Phase

Phase 2 133Phase 1 65Phase 3 34Phase 1/2 19Phase NA 5Phase EARLY_PHASE1 5Phase 2/3 5Phase 4 1

Status

Unknown 4Completed 1

Sponsor Class

OTHER 3OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Oesophagogastric Cancer 1Inflammatory Breast Neoplasms 1Carcinoma, Ductal, Breast 1Breast Diseases 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Lapatinib × Clear all
NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

RemeGen Co., Ltd.

Phase 2/3 Unknown
301 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT03085368 2017-07-28

A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Peking Union Medical College Hospital

Phase 2/3 Unknown
482 enrolled
Breast

Breast Neoplasms

NCT00450203 2016-12-01

ST03

Medical Research Council

Phase 2/3 Unknown
1,103 enrolled
Gastrointestinal

Oesophagogastric Cancer

NCT01426880 2016-02-15

GeparSixto

GBG Forschungs GmbH

Phase 2/3 Completed
595 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT00949455 2015-04-15

LaMB

Queen Mary University of London

Phase 2/3 Unknown
204 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡